Zymeworks(ZYME) - 2024 Q2 - Earnings Call Presentation

Financial Performance - Revenue decreased to $293 million in Q2 2024YTD, compared to $426 million in Q2 2023YTD[9] - R&D Expense decreased to $612 million in Q2 2024YTD, compared to $853 million in Q2 2023YTD[9] - G&A Expense decreased to $315 million in Q2 2024YTD, compared to $387 million in Q2 2023YTD[9] - Net loss was $693 million in Q2 2024YTD, compared to $755 million in Q2 2023YTD[9] - Cash resources were approximately $3959 million as of June 30, 2024[12] Zanidatamab Program - FDA granted Priority Review for zanidatamab BLA as 2L treatment for HER2+ biliary tract cancers (BTC) with a target action date of November 29, 2024[7] - EMA validated the MAA for zanidatamab in 2L BTC[7] - $8 million milestone payment recognized from BeiGene for zanidatamab BLA acceptance in China[7] - Jazz initiated the Phase 3 EmpowHER trial for zanidatamab in late-line HER2+ breast cancer[7] Pipeline Development - IND applications cleared by FDA for ZW191 and ZW171, with first-in-human studies planned for 2H 2024[7] - Discontinuation of zanidatamab zovodotin development program[7] - ZW171 is a 2+1 CD3-Engager Program targeting MSLN, with Phase 1 studies expected in 2H 2024[14] Cash Runway - Anticipated cash runway into 2H 2027, including certain anticipated regulatory milestone payments[12]